knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 22:47:44 - browse：531

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： People with substance use disorder deserve online privacy

WSS

Leading voice in opioid treatment defends methadone clinic system

Midwives could help bridge maternal health disparities in the U.S.

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Nurses recount patients attacks

Free Covid tests will again be offered to all U.S. households

Fed up with FDA, ALS advocates consider a take

entertainment

knowledge

leisure time

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Bluebird, CVS, Contineum

Medical records are filled with copy

5 to watch: Tech startups trying to solve health care's staffing crisis

Cancer drug shortages should be causing more outrage

FDA weighs limits of animal data in assessing artificial wombs

Medical records are filled with copy

AstraZeneca to buy developer of next

After affirmative action ruling, medical educators look to 'holistic review'

Assistant physicians can help address the primary care shortage

Wikipedia

People with substance use disorder deserve online privacy

U.K. researchers warn about biases in medical devices, algorithms

Covid’s new normal has set in amid another rise in cases

Virtual Event: March of the Biosimilars

Virtual Event: March of the Biosimilars

Plastic surgeons increase patient psychiatric screenings

leisure time

hotspot

leisure time

entertainment